What question did this study set out to answer?

To assess real-world treatment patterns and outcomes in hairy cell leukemia, with a focus on BRAF inhibitors.

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort evaluates real-world treatment outcomes in adults with hairy cell leukemia, indicating effective BRAF inhibitor use.

To assess real-world treatment patterns and outcomes in hairy cell leukemia, with a focus on BRAF inhibitors.
Conducted a multicenter retrospective study with 110 adult patients diagnosed with classic hairy cell leukemia.
Evaluated first-line therapies including cladribine, rituximab, and vemurafenib-based regimens.
Analyzed response rates and overall survival outcomes among different treatment groups.
Overall response rate to first-line therapy was 80%, with a complete response rate of 65%.
Median overall survival was 24.4 years across all treated patients.
Patients on vemurafenib-based regimens exhibited an 80% response rate, comparable to purine analogue therapy.

Fradin et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark